nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—MPO—urinary bladder cancer	0.371	0.727	CbGaD
Nabumetone—PTGS2—urinary bladder cancer	0.139	0.273	CbGaD
Nabumetone—MPO—Carboplatin—urinary bladder cancer	0.118	0.342	CbGbCtD
Nabumetone—MPO—Cisplatin—urinary bladder cancer	0.101	0.292	CbGbCtD
Nabumetone—PTGS2—Cisplatin—urinary bladder cancer	0.0348	0.101	CbGbCtD
Nabumetone—PTGS2—Etoposide—urinary bladder cancer	0.0342	0.0991	CbGbCtD
Nabumetone—PTGS1—Etoposide—urinary bladder cancer	0.0288	0.0837	CbGbCtD
Nabumetone—CYP1A2—Fluorouracil—urinary bladder cancer	0.0154	0.0448	CbGbCtD
Nabumetone—CYP1A2—Etoposide—urinary bladder cancer	0.0129	0.0374	CbGbCtD
Nabumetone—Melatonin—MT3—urinary bladder cancer	0.00189	0.444	CrCbGaD
Nabumetone—CYP1A2—urine—urinary bladder cancer	0.00143	0.172	CbGeAlD
Nabumetone—Naproxen—UGT2B7—urinary bladder cancer	0.00129	0.304	CrCbGaD
Nabumetone—MPO—epithelium—urinary bladder cancer	0.00069	0.0827	CbGeAlD
Nabumetone—MPO—renal system—urinary bladder cancer	0.00064	0.0767	CbGeAlD
Nabumetone—Melatonin—MPO—urinary bladder cancer	0.000489	0.115	CrCbGaD
Nabumetone—PTGS1—prostate gland—urinary bladder cancer	0.000445	0.0534	CbGeAlD
Nabumetone—PTGS2—prostate gland—urinary bladder cancer	0.000426	0.0511	CbGeAlD
Nabumetone—PTGS1—seminal vesicle—urinary bladder cancer	0.000377	0.0452	CbGeAlD
Nabumetone—Melatonin—ESR1—urinary bladder cancer	0.000367	0.0864	CrCbGaD
Nabumetone—PTGS2—seminal vesicle—urinary bladder cancer	0.00036	0.0432	CbGeAlD
Nabumetone—CYP1A2—renal system—urinary bladder cancer	0.00035	0.042	CbGeAlD
Nabumetone—PTGS1—epithelium—urinary bladder cancer	0.000327	0.0393	CbGeAlD
Nabumetone—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000315	0.0378	CbGeAlD
Nabumetone—PTGS2—epithelium—urinary bladder cancer	0.000313	0.0375	CbGeAlD
Nabumetone—PTGS1—renal system—urinary bladder cancer	0.000304	0.0364	CbGeAlD
Nabumetone—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000301	0.0362	CbGeAlD
Nabumetone—MPO—lymph node—urinary bladder cancer	0.0003	0.036	CbGeAlD
Nabumetone—PTGS2—renal system—urinary bladder cancer	0.00029	0.0348	CbGeAlD
Nabumetone—PTGS2—urethra—urinary bladder cancer	0.000285	0.0342	CbGeAlD
Nabumetone—PTGS1—female reproductive system—urinary bladder cancer	0.000243	0.0292	CbGeAlD
Nabumetone—PTGS2—female reproductive system—urinary bladder cancer	0.000232	0.0279	CbGeAlD
Nabumetone—PTGS1—vagina—urinary bladder cancer	0.00022	0.0264	CbGeAlD
Nabumetone—Naproxen—PTGS2—urinary bladder cancer	0.000213	0.0501	CrCbGaD
Nabumetone—PTGS2—vagina—urinary bladder cancer	0.00021	0.0252	CbGeAlD
Nabumetone—PTGS1—lymph node—urinary bladder cancer	0.000142	0.0171	CbGeAlD
Nabumetone—MPO—Folate Metabolism—TP53—urinary bladder cancer	0.000138	0.00356	CbGpPWpGaD
Nabumetone—PTGS2—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000137	0.00355	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000137	0.00353	CbGpPWpGaD
Nabumetone—PTGS2—lymph node—urinary bladder cancer	0.000136	0.0163	CbGeAlD
Nabumetone—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000135	0.00348	CbGpPWpGaD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—urinary bladder cancer	0.000134	0.00347	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000134	0.00346	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000131	0.00339	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000131	0.00339	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—urinary bladder cancer	0.000131	0.00339	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000129	0.00335	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000129	0.00335	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000128	0.0033	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000128	0.0033	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—KRAS—urinary bladder cancer	0.000128	0.0033	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—HPGDS—urinary bladder cancer	0.000126	0.00326	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—TNF—urinary bladder cancer	0.000124	0.0032	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—GSTT1—urinary bladder cancer	0.000122	0.00316	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000122	0.00315	CbGpPWpGaD
Nabumetone—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000121	0.00313	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000121	0.00312	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—urinary bladder cancer	0.000119	0.00308	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000118	0.00306	CbGpPWpGaD
Nabumetone—PTGS1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000118	0.00305	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000118	0.00304	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000117	0.00302	CbGpPWpGaD
Nabumetone—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000114	0.00122	CcSEcCtD
Nabumetone—Angina pectoris—Epirubicin—urinary bladder cancer	0.000114	0.00122	CcSEcCtD
Nabumetone—Anorexia—Etoposide—urinary bladder cancer	0.000113	0.00121	CcSEcCtD
Nabumetone—Diarrhoea—Thiotepa—urinary bladder cancer	0.000113	0.00121	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000113	0.00121	CcSEcCtD
Nabumetone—Decreased appetite—Cisplatin—urinary bladder cancer	0.000113	0.00121	CcSEcCtD
Nabumetone—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000113	0.00121	CcSEcCtD
Nabumetone—Pneumonia—Methotrexate—urinary bladder cancer	0.000112	0.0012	CcSEcCtD
Nabumetone—Depression—Methotrexate—urinary bladder cancer	0.000111	0.00119	CcSEcCtD
Nabumetone—Gastritis—Doxorubicin—urinary bladder cancer	0.000111	0.00119	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000111	0.00118	CcSEcCtD
Nabumetone—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00011	0.00118	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.00011	0.00284	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.00011	0.00284	CbGpPWpGaD
Nabumetone—Renal failure—Methotrexate—urinary bladder cancer	0.00011	0.00117	CcSEcCtD
Nabumetone—Dysuria—Epirubicin—urinary bladder cancer	0.00011	0.00117	CcSEcCtD
Nabumetone—Dizziness—Thiotepa—urinary bladder cancer	0.000109	0.00117	CcSEcCtD
Nabumetone—Stomatitis—Methotrexate—urinary bladder cancer	0.000109	0.00116	CcSEcCtD
Nabumetone—Urticaria—Fluorouracil—urinary bladder cancer	0.000109	0.00116	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—HRAS—urinary bladder cancer	0.000109	0.0028	CbGpPWpGaD
Nabumetone—Dysphagia—Doxorubicin—urinary bladder cancer	0.000108	0.00116	CcSEcCtD
Nabumetone—Asthma—Doxorubicin—urinary bladder cancer	0.000108	0.00116	CcSEcCtD
Nabumetone—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000108	0.00116	CcSEcCtD
Nabumetone—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000107	0.00114	CcSEcCtD
Nabumetone—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000107	0.00114	CcSEcCtD
Nabumetone—Paraesthesia—Etoposide—urinary bladder cancer	0.000107	0.00114	CcSEcCtD
Nabumetone—Weight increased—Epirubicin—urinary bladder cancer	0.000107	0.00114	CcSEcCtD
Nabumetone—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.000107	0.00275	CbGpPWpGaD
Nabumetone—Haematuria—Methotrexate—urinary bladder cancer	0.000106	0.00114	CcSEcCtD
Nabumetone—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000106	0.00114	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000106	0.00275	CbGpPWpGaD
Nabumetone—Weight decreased—Epirubicin—urinary bladder cancer	0.000106	0.00113	CcSEcCtD
Nabumetone—Dyspnoea—Etoposide—urinary bladder cancer	0.000106	0.00113	CcSEcCtD
Nabumetone—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000106	0.00113	CcSEcCtD
Nabumetone—Somnolence—Etoposide—urinary bladder cancer	0.000106	0.00113	CcSEcCtD
Nabumetone—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000106	0.00113	CcSEcCtD
Nabumetone—Vomiting—Thiotepa—urinary bladder cancer	0.000105	0.00113	CcSEcCtD
Nabumetone—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000105	0.00272	CbGpPWpGaD
Nabumetone—Pneumonia—Epirubicin—urinary bladder cancer	0.000105	0.00112	CcSEcCtD
Nabumetone—Rash—Thiotepa—urinary bladder cancer	0.000104	0.00112	CcSEcCtD
Nabumetone—Dermatitis—Thiotepa—urinary bladder cancer	0.000104	0.00112	CcSEcCtD
Nabumetone—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000104	0.00112	CcSEcCtD
Nabumetone—Headache—Thiotepa—urinary bladder cancer	0.000104	0.00111	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000104	0.00111	CcSEcCtD
Nabumetone—Decreased appetite—Etoposide—urinary bladder cancer	0.000103	0.00111	CcSEcCtD
Nabumetone—Renal failure—Epirubicin—urinary bladder cancer	0.000103	0.0011	CcSEcCtD
Nabumetone—Body temperature increased—Cisplatin—urinary bladder cancer	0.000103	0.0011	CcSEcCtD
Nabumetone—Fatigue—Etoposide—urinary bladder cancer	0.000103	0.0011	CcSEcCtD
Nabumetone—Stomatitis—Epirubicin—urinary bladder cancer	0.000102	0.00109	CcSEcCtD
Nabumetone—Jaundice—Epirubicin—urinary bladder cancer	0.000102	0.00109	CcSEcCtD
Nabumetone—Constipation—Etoposide—urinary bladder cancer	0.000102	0.00109	CcSEcCtD
Nabumetone—Dysuria—Doxorubicin—urinary bladder cancer	0.000101	0.00109	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000101	0.00262	CbGpPWpGaD
Nabumetone—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000101	0.00108	CcSEcCtD
Nabumetone—Haemoglobin—Methotrexate—urinary bladder cancer	0.000101	0.00108	CcSEcCtD
Nabumetone—Haemorrhage—Methotrexate—urinary bladder cancer	0.0001	0.00107	CcSEcCtD
Nabumetone—Asthenia—Gemcitabine—urinary bladder cancer	9.99e-05	0.00107	CcSEcCtD
Nabumetone—Haematuria—Epirubicin—urinary bladder cancer	9.97e-05	0.00107	CcSEcCtD
Nabumetone—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	9.9e-05	0.00106	CcSEcCtD
Nabumetone—Weight increased—Doxorubicin—urinary bladder cancer	9.87e-05	0.00106	CcSEcCtD
Nabumetone—Pruritus—Gemcitabine—urinary bladder cancer	9.85e-05	0.00105	CcSEcCtD
Nabumetone—Nausea—Thiotepa—urinary bladder cancer	9.83e-05	0.00105	CcSEcCtD
Nabumetone—Weight decreased—Doxorubicin—urinary bladder cancer	9.81e-05	0.00105	CcSEcCtD
Nabumetone—Feeling abnormal—Etoposide—urinary bladder cancer	9.8e-05	0.00105	CcSEcCtD
Nabumetone—Hyperglycaemia—Doxorubicin—urinary bladder cancer	9.78e-05	0.00105	CcSEcCtD
Nabumetone—Agranulocytosis—Epirubicin—urinary bladder cancer	9.75e-05	0.00104	CcSEcCtD
Nabumetone—Pneumonia—Doxorubicin—urinary bladder cancer	9.73e-05	0.00104	CcSEcCtD
Nabumetone—Gastrointestinal pain—Etoposide—urinary bladder cancer	9.73e-05	0.00104	CcSEcCtD
Nabumetone—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	9.7e-05	0.0025	CbGpPWpGaD
Nabumetone—Pruritus—Fluorouracil—urinary bladder cancer	9.69e-05	0.00104	CcSEcCtD
Nabumetone—Visual impairment—Methotrexate—urinary bladder cancer	9.66e-05	0.00103	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	9.59e-05	0.00103	CcSEcCtD
Nabumetone—Hypersensitivity—Cisplatin—urinary bladder cancer	9.56e-05	0.00102	CcSEcCtD
Nabumetone—Diarrhoea—Gemcitabine—urinary bladder cancer	9.53e-05	0.00102	CcSEcCtD
Nabumetone—Renal failure—Doxorubicin—urinary bladder cancer	9.51e-05	0.00102	CcSEcCtD
Nabumetone—Erythema multiforme—Methotrexate—urinary bladder cancer	9.48e-05	0.00101	CcSEcCtD
Nabumetone—Urticaria—Etoposide—urinary bladder cancer	9.45e-05	0.00101	CcSEcCtD
Nabumetone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	9.44e-05	0.00244	CbGpPWpGaD
Nabumetone—Haemoglobin—Epirubicin—urinary bladder cancer	9.43e-05	0.00101	CcSEcCtD
Nabumetone—Jaundice—Doxorubicin—urinary bladder cancer	9.43e-05	0.00101	CcSEcCtD
Nabumetone—Stomatitis—Doxorubicin—urinary bladder cancer	9.43e-05	0.00101	CcSEcCtD
Nabumetone—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	9.4e-05	0.00243	CbGpPWpGaD
Nabumetone—Body temperature increased—Etoposide—urinary bladder cancer	9.4e-05	0.00101	CcSEcCtD
Nabumetone—Abdominal pain—Etoposide—urinary bladder cancer	9.4e-05	0.00101	CcSEcCtD
Nabumetone—Haemorrhage—Epirubicin—urinary bladder cancer	9.38e-05	0.001	CcSEcCtD
Nabumetone—Diarrhoea—Fluorouracil—urinary bladder cancer	9.37e-05	0.001	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	9.35e-05	0.00242	CbGpPWpGaD
Nabumetone—Tinnitus—Methotrexate—urinary bladder cancer	9.35e-05	0.001	CcSEcCtD
Nabumetone—Asthenia—Cisplatin—urinary bladder cancer	9.31e-05	0.000996	CcSEcCtD
Nabumetone—Haematuria—Doxorubicin—urinary bladder cancer	9.22e-05	0.000987	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	9.22e-05	0.00238	CbGpPWpGaD
Nabumetone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	9.19e-05	0.00237	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	9.16e-05	0.00237	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	9.11e-05	0.00235	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	9.1e-05	0.00235	CbGpPWpGaD
Nabumetone—Dizziness—Fluorouracil—urinary bladder cancer	9.06e-05	0.000969	CcSEcCtD
Nabumetone—Visual impairment—Epirubicin—urinary bladder cancer	9.04e-05	0.000967	CcSEcCtD
Nabumetone—Agranulocytosis—Doxorubicin—urinary bladder cancer	9.03e-05	0.000966	CcSEcCtD
Nabumetone—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	9.02e-05	0.00233	CbGpPWpGaD
Nabumetone—Chills—Methotrexate—urinary bladder cancer	9e-05	0.000963	CcSEcCtD
Nabumetone—Diarrhoea—Cisplatin—urinary bladder cancer	8.88e-05	0.00095	CcSEcCtD
Nabumetone—Erythema multiforme—Epirubicin—urinary bladder cancer	8.87e-05	0.000949	CcSEcCtD
Nabumetone—Alopecia—Methotrexate—urinary bladder cancer	8.86e-05	0.000948	CcSEcCtD
Nabumetone—Vomiting—Gemcitabine—urinary bladder cancer	8.86e-05	0.000947	CcSEcCtD
Nabumetone—Rash—Gemcitabine—urinary bladder cancer	8.78e-05	0.00094	CcSEcCtD
Nabumetone—Dermatitis—Gemcitabine—urinary bladder cancer	8.77e-05	0.000939	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	8.76e-05	0.00226	CbGpPWpGaD
Nabumetone—Hypersensitivity—Etoposide—urinary bladder cancer	8.76e-05	0.000937	CcSEcCtD
Nabumetone—Tinnitus—Epirubicin—urinary bladder cancer	8.75e-05	0.000936	CcSEcCtD
Nabumetone—Haemoglobin—Doxorubicin—urinary bladder cancer	8.73e-05	0.000934	CcSEcCtD
Nabumetone—Headache—Gemcitabine—urinary bladder cancer	8.73e-05	0.000933	CcSEcCtD
Nabumetone—Vomiting—Fluorouracil—urinary bladder cancer	8.71e-05	0.000932	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	8.69e-05	0.00225	CbGpPWpGaD
Nabumetone—Haemorrhage—Doxorubicin—urinary bladder cancer	8.68e-05	0.000929	CcSEcCtD
Nabumetone—Rash—Fluorouracil—urinary bladder cancer	8.63e-05	0.000924	CcSEcCtD
Nabumetone—Dermatitis—Fluorouracil—urinary bladder cancer	8.63e-05	0.000923	CcSEcCtD
Nabumetone—Headache—Fluorouracil—urinary bladder cancer	8.58e-05	0.000918	CcSEcCtD
Nabumetone—Asthenia—Etoposide—urinary bladder cancer	8.53e-05	0.000913	CcSEcCtD
Nabumetone—PTGS1—Biological oxidations—GSTP1—urinary bladder cancer	8.49e-05	0.00219	CbGpPWpGaD
Nabumetone—Chills—Epirubicin—urinary bladder cancer	8.42e-05	0.000901	CcSEcCtD
Nabumetone—Pruritus—Etoposide—urinary bladder cancer	8.41e-05	0.0009	CcSEcCtD
Nabumetone—Arrhythmia—Epirubicin—urinary bladder cancer	8.38e-05	0.000897	CcSEcCtD
Nabumetone—Visual impairment—Doxorubicin—urinary bladder cancer	8.37e-05	0.000895	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	8.34e-05	0.00215	CbGpPWpGaD
Nabumetone—Alopecia—Epirubicin—urinary bladder cancer	8.29e-05	0.000887	CcSEcCtD
Nabumetone—Nausea—Gemcitabine—urinary bladder cancer	8.27e-05	0.000885	CcSEcCtD
Nabumetone—Vomiting—Cisplatin—urinary bladder cancer	8.25e-05	0.000883	CcSEcCtD
Nabumetone—Erythema multiforme—Doxorubicin—urinary bladder cancer	8.21e-05	0.000878	CcSEcCtD
Nabumetone—Rash—Cisplatin—urinary bladder cancer	8.19e-05	0.000876	CcSEcCtD
Nabumetone—Dermatitis—Cisplatin—urinary bladder cancer	8.18e-05	0.000875	CcSEcCtD
Nabumetone—Diarrhoea—Etoposide—urinary bladder cancer	8.14e-05	0.000871	CcSEcCtD
Nabumetone—Nausea—Fluorouracil—urinary bladder cancer	8.13e-05	0.00087	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	8.11e-05	0.0021	CbGpPWpGaD
Nabumetone—Ill-defined disorder—Methotrexate—urinary bladder cancer	8.1e-05	0.000866	CcSEcCtD
Nabumetone—Tinnitus—Doxorubicin—urinary bladder cancer	8.1e-05	0.000866	CcSEcCtD
Nabumetone—Anaemia—Methotrexate—urinary bladder cancer	8.07e-05	0.000863	CcSEcCtD
Nabumetone—Flatulence—Epirubicin—urinary bladder cancer	8.05e-05	0.000861	CcSEcCtD
Nabumetone—Tension—Epirubicin—urinary bladder cancer	8.02e-05	0.000858	CcSEcCtD
Nabumetone—Nervousness—Epirubicin—urinary bladder cancer	7.93e-05	0.000849	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	7.91e-05	0.00204	CbGpPWpGaD
Nabumetone—Malaise—Methotrexate—urinary bladder cancer	7.87e-05	0.000842	CcSEcCtD
Nabumetone—Dizziness—Etoposide—urinary bladder cancer	7.86e-05	0.000841	CcSEcCtD
Nabumetone—Vertigo—Methotrexate—urinary bladder cancer	7.84e-05	0.000839	CcSEcCtD
Nabumetone—Leukopenia—Methotrexate—urinary bladder cancer	7.81e-05	0.000836	CcSEcCtD
Nabumetone—PTGS1—Biological oxidations—GSTM1—urinary bladder cancer	7.8e-05	0.00202	CbGpPWpGaD
Nabumetone—Chills—Doxorubicin—urinary bladder cancer	7.79e-05	0.000833	CcSEcCtD
Nabumetone—Arrhythmia—Doxorubicin—urinary bladder cancer	7.76e-05	0.00083	CcSEcCtD
Nabumetone—Nausea—Cisplatin—urinary bladder cancer	7.71e-05	0.000825	CcSEcCtD
Nabumetone—Alopecia—Doxorubicin—urinary bladder cancer	7.67e-05	0.000821	CcSEcCtD
Nabumetone—Cough—Methotrexate—urinary bladder cancer	7.62e-05	0.000815	CcSEcCtD
Nabumetone—Ill-defined disorder—Epirubicin—urinary bladder cancer	7.58e-05	0.000811	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	7.56e-05	0.00195	CbGpPWpGaD
Nabumetone—Vomiting—Etoposide—urinary bladder cancer	7.56e-05	0.000809	CcSEcCtD
Nabumetone—Anaemia—Epirubicin—urinary bladder cancer	7.55e-05	0.000808	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	7.52e-05	0.00194	CbGpPWpGaD
Nabumetone—Agitation—Epirubicin—urinary bladder cancer	7.51e-05	0.000803	CcSEcCtD
Nabumetone—Rash—Etoposide—urinary bladder cancer	7.5e-05	0.000802	CcSEcCtD
Nabumetone—Dermatitis—Etoposide—urinary bladder cancer	7.49e-05	0.000802	CcSEcCtD
Nabumetone—Headache—Etoposide—urinary bladder cancer	7.45e-05	0.000797	CcSEcCtD
Nabumetone—Flatulence—Doxorubicin—urinary bladder cancer	7.45e-05	0.000797	CcSEcCtD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	7.43e-05	0.00192	CbGpPWpGaD
Nabumetone—Tension—Doxorubicin—urinary bladder cancer	7.42e-05	0.000794	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	7.38e-05	0.00191	CbGpPWpGaD
Nabumetone—Malaise—Epirubicin—urinary bladder cancer	7.37e-05	0.000788	CcSEcCtD
Nabumetone—Discomfort—Methotrexate—urinary bladder cancer	7.34e-05	0.000786	CcSEcCtD
Nabumetone—Nervousness—Doxorubicin—urinary bladder cancer	7.34e-05	0.000785	CcSEcCtD
Nabumetone—Vertigo—Epirubicin—urinary bladder cancer	7.34e-05	0.000785	CcSEcCtD
Nabumetone—Syncope—Epirubicin—urinary bladder cancer	7.33e-05	0.000784	CcSEcCtD
Nabumetone—Leukopenia—Epirubicin—urinary bladder cancer	7.31e-05	0.000782	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	7.27e-05	0.00188	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	7.24e-05	0.00187	CbGpPWpGaD
Nabumetone—Palpitations—Epirubicin—urinary bladder cancer	7.22e-05	0.000772	CcSEcCtD
Nabumetone—Confusional state—Methotrexate—urinary bladder cancer	7.18e-05	0.000768	CcSEcCtD
Nabumetone—Loss of consciousness—Epirubicin—urinary bladder cancer	7.18e-05	0.000768	CcSEcCtD
Nabumetone—Cough—Epirubicin—urinary bladder cancer	7.13e-05	0.000763	CcSEcCtD
Nabumetone—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.12e-05	0.000762	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	7.11e-05	0.00184	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	7.1e-05	0.00183	CbGpPWpGaD
Nabumetone—Nausea—Etoposide—urinary bladder cancer	7.06e-05	0.000756	CcSEcCtD
Nabumetone—Hypertension—Epirubicin—urinary bladder cancer	7.05e-05	0.000755	CcSEcCtD
Nabumetone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	7.01e-05	0.00075	CcSEcCtD
Nabumetone—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	7e-05	0.00181	CbGpPWpGaD
Nabumetone—Anaemia—Doxorubicin—urinary bladder cancer	6.99e-05	0.000747	CcSEcCtD
Nabumetone—Thrombocytopenia—Methotrexate—urinary bladder cancer	6.97e-05	0.000746	CcSEcCtD
Nabumetone—Agitation—Doxorubicin—urinary bladder cancer	6.95e-05	0.000743	CcSEcCtD
Nabumetone—Anxiety—Epirubicin—urinary bladder cancer	6.93e-05	0.000741	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	6.9e-05	0.00178	CbGpPWpGaD
Nabumetone—Hyperhidrosis—Methotrexate—urinary bladder cancer	6.89e-05	0.000737	CcSEcCtD
Nabumetone—Discomfort—Epirubicin—urinary bladder cancer	6.87e-05	0.000735	CcSEcCtD
Nabumetone—Malaise—Doxorubicin—urinary bladder cancer	6.82e-05	0.000729	CcSEcCtD
Nabumetone—Dry mouth—Epirubicin—urinary bladder cancer	6.8e-05	0.000728	CcSEcCtD
Nabumetone—Vertigo—Doxorubicin—urinary bladder cancer	6.79e-05	0.000726	CcSEcCtD
Nabumetone—Anorexia—Methotrexate—urinary bladder cancer	6.79e-05	0.000726	CcSEcCtD
Nabumetone—Syncope—Doxorubicin—urinary bladder cancer	6.78e-05	0.000725	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	6.77e-05	0.00175	CbGpPWpGaD
Nabumetone—Leukopenia—Doxorubicin—urinary bladder cancer	6.77e-05	0.000724	CcSEcCtD
Nabumetone—Confusional state—Epirubicin—urinary bladder cancer	6.72e-05	0.000719	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	6.71e-05	0.00173	CbGpPWpGaD
Nabumetone—Palpitations—Doxorubicin—urinary bladder cancer	6.68e-05	0.000715	CcSEcCtD
Nabumetone—Anaphylactic shock—Epirubicin—urinary bladder cancer	6.67e-05	0.000713	CcSEcCtD
Nabumetone—Oedema—Epirubicin—urinary bladder cancer	6.67e-05	0.000713	CcSEcCtD
Nabumetone—Loss of consciousness—Doxorubicin—urinary bladder cancer	6.64e-05	0.000711	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	6.62e-05	0.00171	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	6.6e-05	0.00171	CbGpPWpGaD
Nabumetone—Cough—Doxorubicin—urinary bladder cancer	6.6e-05	0.000706	CcSEcCtD
Nabumetone—Shock—Epirubicin—urinary bladder cancer	6.56e-05	0.000702	CcSEcCtD
Nabumetone—Thrombocytopenia—Epirubicin—urinary bladder cancer	6.53e-05	0.000698	CcSEcCtD
Nabumetone—Hypertension—Doxorubicin—urinary bladder cancer	6.53e-05	0.000698	CcSEcCtD
Nabumetone—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	6.52e-05	0.00168	CbGpPWpGaD
Nabumetone—Hyperhidrosis—Epirubicin—urinary bladder cancer	6.44e-05	0.00069	CcSEcCtD
Nabumetone—Insomnia—Methotrexate—urinary bladder cancer	6.44e-05	0.000689	CcSEcCtD
Nabumetone—Anxiety—Doxorubicin—urinary bladder cancer	6.41e-05	0.000686	CcSEcCtD
Nabumetone—Paraesthesia—Methotrexate—urinary bladder cancer	6.4e-05	0.000684	CcSEcCtD
Nabumetone—Discomfort—Doxorubicin—urinary bladder cancer	6.36e-05	0.00068	CcSEcCtD
Nabumetone—Anorexia—Epirubicin—urinary bladder cancer	6.35e-05	0.00068	CcSEcCtD
Nabumetone—Dyspnoea—Methotrexate—urinary bladder cancer	6.35e-05	0.000679	CcSEcCtD
Nabumetone—Somnolence—Methotrexate—urinary bladder cancer	6.33e-05	0.000678	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	6.33e-05	0.00164	CbGpPWpGaD
Nabumetone—Dry mouth—Doxorubicin—urinary bladder cancer	6.29e-05	0.000673	CcSEcCtD
Nabumetone—Dyspepsia—Methotrexate—urinary bladder cancer	6.27e-05	0.000671	CcSEcCtD
Nabumetone—Confusional state—Doxorubicin—urinary bladder cancer	6.22e-05	0.000665	CcSEcCtD
Nabumetone—Decreased appetite—Methotrexate—urinary bladder cancer	6.19e-05	0.000663	CcSEcCtD
Nabumetone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.17e-05	0.00066	CcSEcCtD
Nabumetone—Oedema—Doxorubicin—urinary bladder cancer	6.17e-05	0.00066	CcSEcCtD
Nabumetone—Fatigue—Methotrexate—urinary bladder cancer	6.14e-05	0.000657	CcSEcCtD
Nabumetone—Shock—Doxorubicin—urinary bladder cancer	6.07e-05	0.000649	CcSEcCtD
Nabumetone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.04e-05	0.000646	CcSEcCtD
Nabumetone—Insomnia—Epirubicin—urinary bladder cancer	6.03e-05	0.000645	CcSEcCtD
Nabumetone—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	5.99e-05	0.00155	CbGpPWpGaD
Nabumetone—Paraesthesia—Epirubicin—urinary bladder cancer	5.99e-05	0.00064	CcSEcCtD
Nabumetone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.96e-05	0.000638	CcSEcCtD
Nabumetone—Dyspnoea—Epirubicin—urinary bladder cancer	5.94e-05	0.000636	CcSEcCtD
Nabumetone—Somnolence—Epirubicin—urinary bladder cancer	5.93e-05	0.000634	CcSEcCtD
Nabumetone—Anorexia—Doxorubicin—urinary bladder cancer	5.88e-05	0.000629	CcSEcCtD
Nabumetone—Feeling abnormal—Methotrexate—urinary bladder cancer	5.87e-05	0.000628	CcSEcCtD
Nabumetone—Dyspepsia—Epirubicin—urinary bladder cancer	5.87e-05	0.000628	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	5.87e-05	0.00152	CbGpPWpGaD
Nabumetone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5.83e-05	0.000623	CcSEcCtD
Nabumetone—Decreased appetite—Epirubicin—urinary bladder cancer	5.8e-05	0.00062	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	5.76e-05	0.00149	CbGpPWpGaD
Nabumetone—Fatigue—Epirubicin—urinary bladder cancer	5.75e-05	0.000615	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	5.74e-05	0.00148	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	5.71e-05	0.00147	CbGpPWpGaD
Nabumetone—Constipation—Epirubicin—urinary bladder cancer	5.7e-05	0.00061	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	5.67e-05	0.00147	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	5.67e-05	0.00147	CbGpPWpGaD
Nabumetone—Urticaria—Methotrexate—urinary bladder cancer	5.66e-05	0.000605	CcSEcCtD
Nabumetone—Abdominal pain—Methotrexate—urinary bladder cancer	5.63e-05	0.000602	CcSEcCtD
Nabumetone—Body temperature increased—Methotrexate—urinary bladder cancer	5.63e-05	0.000602	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	5.6e-05	0.00145	CbGpPWpGaD
Nabumetone—Insomnia—Doxorubicin—urinary bladder cancer	5.58e-05	0.000597	CcSEcCtD
Nabumetone—Paraesthesia—Doxorubicin—urinary bladder cancer	5.54e-05	0.000593	CcSEcCtD
Nabumetone—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	5.5e-05	0.00142	CbGpPWpGaD
Nabumetone—Dyspnoea—Doxorubicin—urinary bladder cancer	5.5e-05	0.000588	CcSEcCtD
Nabumetone—Feeling abnormal—Epirubicin—urinary bladder cancer	5.49e-05	0.000588	CcSEcCtD
Nabumetone—Somnolence—Doxorubicin—urinary bladder cancer	5.48e-05	0.000587	CcSEcCtD
Nabumetone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.45e-05	0.000583	CcSEcCtD
Nabumetone—Dyspepsia—Doxorubicin—urinary bladder cancer	5.43e-05	0.000581	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	5.41e-05	0.0014	CbGpPWpGaD
Nabumetone—Decreased appetite—Doxorubicin—urinary bladder cancer	5.36e-05	0.000574	CcSEcCtD
Nabumetone—Fatigue—Doxorubicin—urinary bladder cancer	5.32e-05	0.000569	CcSEcCtD
Nabumetone—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	5.31e-05	0.00137	CbGpPWpGaD
Nabumetone—Urticaria—Epirubicin—urinary bladder cancer	5.3e-05	0.000567	CcSEcCtD
Nabumetone—Constipation—Doxorubicin—urinary bladder cancer	5.27e-05	0.000564	CcSEcCtD
Nabumetone—Body temperature increased—Epirubicin—urinary bladder cancer	5.27e-05	0.000564	CcSEcCtD
Nabumetone—Abdominal pain—Epirubicin—urinary bladder cancer	5.27e-05	0.000564	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	5.26e-05	0.00136	CbGpPWpGaD
Nabumetone—Hypersensitivity—Methotrexate—urinary bladder cancer	5.25e-05	0.000562	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	5.21e-05	0.00135	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTZ1—urinary bladder cancer	5.2e-05	0.00134	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	5.15e-05	0.00133	CbGpPWpGaD
Nabumetone—Asthenia—Methotrexate—urinary bladder cancer	5.11e-05	0.000547	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	5.1e-05	0.00132	CbGpPWpGaD
Nabumetone—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.08e-05	0.000544	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—TNF—urinary bladder cancer	5.07e-05	0.00131	CbGpPWpGaD
Nabumetone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.04e-05	0.00054	CcSEcCtD
Nabumetone—Pruritus—Methotrexate—urinary bladder cancer	5.04e-05	0.000539	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	4.96e-05	0.00128	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTO2—urinary bladder cancer	4.93e-05	0.00127	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NAT1—urinary bladder cancer	4.93e-05	0.00127	CbGpPWpGaD
Nabumetone—Hypersensitivity—Epirubicin—urinary bladder cancer	4.91e-05	0.000525	CcSEcCtD
Nabumetone—Urticaria—Doxorubicin—urinary bladder cancer	4.9e-05	0.000524	CcSEcCtD
Nabumetone—Body temperature increased—Doxorubicin—urinary bladder cancer	4.88e-05	0.000522	CcSEcCtD
Nabumetone—Abdominal pain—Doxorubicin—urinary bladder cancer	4.88e-05	0.000522	CcSEcCtD
Nabumetone—Diarrhoea—Methotrexate—urinary bladder cancer	4.87e-05	0.000521	CcSEcCtD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.85e-05	0.00125	CbGpPWpGaD
Nabumetone—Asthenia—Epirubicin—urinary bladder cancer	4.78e-05	0.000512	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	4.72e-05	0.00122	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	4.72e-05	0.00122	CbGpPWpGaD
Nabumetone—Pruritus—Epirubicin—urinary bladder cancer	4.72e-05	0.000505	CcSEcCtD
Nabumetone—Dizziness—Methotrexate—urinary bladder cancer	4.71e-05	0.000504	CcSEcCtD
Nabumetone—PTGS2—Disease—GSTO2—urinary bladder cancer	4.67e-05	0.00121	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	4.59e-05	0.00119	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	4.59e-05	0.00119	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	4.58e-05	0.00118	CbGpPWpGaD
Nabumetone—Diarrhoea—Epirubicin—urinary bladder cancer	4.56e-05	0.000488	CcSEcCtD
Nabumetone—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.54e-05	0.000486	CcSEcCtD
Nabumetone—Vomiting—Methotrexate—urinary bladder cancer	4.53e-05	0.000485	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.51e-05	0.00117	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	4.51e-05	0.00116	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.49e-05	0.00116	CbGpPWpGaD
Nabumetone—Rash—Methotrexate—urinary bladder cancer	4.49e-05	0.000481	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	4.49e-05	0.00116	CbGpPWpGaD
Nabumetone—Dermatitis—Methotrexate—urinary bladder cancer	4.49e-05	0.00048	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.47e-05	0.00116	CbGpPWpGaD
Nabumetone—Headache—Methotrexate—urinary bladder cancer	4.46e-05	0.000477	CcSEcCtD
Nabumetone—Asthenia—Doxorubicin—urinary bladder cancer	4.43e-05	0.000473	CcSEcCtD
Nabumetone—Dizziness—Epirubicin—urinary bladder cancer	4.41e-05	0.000472	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	4.37e-05	0.00113	CbGpPWpGaD
Nabumetone—Pruritus—Doxorubicin—urinary bladder cancer	4.36e-05	0.000467	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	4.26e-05	0.0011	CbGpPWpGaD
Nabumetone—Vomiting—Epirubicin—urinary bladder cancer	4.24e-05	0.000453	CcSEcCtD
Nabumetone—Nausea—Methotrexate—urinary bladder cancer	4.23e-05	0.000453	CcSEcCtD
Nabumetone—Diarrhoea—Doxorubicin—urinary bladder cancer	4.22e-05	0.000452	CcSEcCtD
Nabumetone—Rash—Epirubicin—urinary bladder cancer	4.2e-05	0.00045	CcSEcCtD
Nabumetone—Dermatitis—Epirubicin—urinary bladder cancer	4.2e-05	0.000449	CcSEcCtD
Nabumetone—Headache—Epirubicin—urinary bladder cancer	4.18e-05	0.000447	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	4.15e-05	0.00107	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	4.14e-05	0.00107	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	4.13e-05	0.00107	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	4.11e-05	0.00106	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	4.09e-05	0.00106	CbGpPWpGaD
Nabumetone—Dizziness—Doxorubicin—urinary bladder cancer	4.08e-05	0.000436	CcSEcCtD
Nabumetone—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	4.06e-05	0.00105	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	4.03e-05	0.00104	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	4.02e-05	0.00104	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	4.02e-05	0.00104	CbGpPWpGaD
Nabumetone—Nausea—Epirubicin—urinary bladder cancer	3.96e-05	0.000424	CcSEcCtD
Nabumetone—Vomiting—Doxorubicin—urinary bladder cancer	3.92e-05	0.00042	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.92e-05	0.00101	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTO2—urinary bladder cancer	3.91e-05	0.00101	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NAT1—urinary bladder cancer	3.91e-05	0.00101	CbGpPWpGaD
Nabumetone—Rash—Doxorubicin—urinary bladder cancer	3.89e-05	0.000416	CcSEcCtD
Nabumetone—Dermatitis—Doxorubicin—urinary bladder cancer	3.89e-05	0.000416	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.87e-05	0.001	CbGpPWpGaD
Nabumetone—Headache—Doxorubicin—urinary bladder cancer	3.86e-05	0.000413	CcSEcCtD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.85e-05	0.000994	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	3.83e-05	0.00099	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	3.83e-05	0.00099	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	3.83e-05	0.00099	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	3.81e-05	0.000985	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	3.8e-05	0.000982	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.76e-05	0.000972	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PRSS3—urinary bladder cancer	3.74e-05	0.000965	CbGpPWpGaD
Nabumetone—Nausea—Doxorubicin—urinary bladder cancer	3.66e-05	0.000392	CcSEcCtD
Nabumetone—PTGS2—Disease—SLC19A1—urinary bladder cancer	3.63e-05	0.000939	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	3.58e-05	0.000925	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PRSS3—urinary bladder cancer	3.54e-05	0.000915	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	3.53e-05	0.000911	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	3.5e-05	0.000905	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.46e-05	0.000893	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	3.42e-05	0.000884	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HDAC4—urinary bladder cancer	3.38e-05	0.000873	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	3.35e-05	0.000864	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.28e-05	0.000848	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	3.23e-05	0.000834	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	3.22e-05	0.000833	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	3.19e-05	0.000823	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	3.04e-05	0.000786	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3e-05	0.000774	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—TYMP—urinary bladder cancer	2.99e-05	0.000772	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PRSS3—urinary bladder cancer	2.97e-05	0.000766	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.9e-05	0.000749	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.87e-05	0.000741	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	2.81e-05	0.000726	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.81e-05	0.000725	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.8e-05	0.000723	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NAT2—urinary bladder cancer	2.7e-05	0.000698	CbGpPWpGaD
Nabumetone—PTGS2—Disease—LIG1—urinary bladder cancer	2.68e-05	0.000693	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.67e-05	0.00069	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.6e-05	0.000671	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.38e-05	0.000614	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—TYMP—urinary bladder cancer	2.37e-05	0.000613	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	2.34e-05	0.000603	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—RRM2—urinary bladder cancer	2.33e-05	0.000602	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.33e-05	0.000601	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.28e-05	0.000588	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.28e-05	0.000588	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	2.21e-05	0.000572	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NAT1—urinary bladder cancer	2.21e-05	0.000572	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.18e-05	0.000563	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.17e-05	0.00056	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ENO2—urinary bladder cancer	2.16e-05	0.000558	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—HPGDS—urinary bladder cancer	2.16e-05	0.000558	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.15e-05	0.000555	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.15e-05	0.000555	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NAT2—urinary bladder cancer	2.14e-05	0.000554	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTT1—urinary bladder cancer	2.09e-05	0.000541	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.06e-05	0.000533	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ENO2—urinary bladder cancer	2.05e-05	0.000529	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	2.03e-05	0.000523	CbGpPWpGaD
Nabumetone—PTGS2—Disease—RBX1—urinary bladder cancer	1.94e-05	0.000501	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.91e-05	0.000494	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—RRM2—urinary bladder cancer	1.85e-05	0.000478	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	1.82e-05	0.000471	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NQO1—urinary bladder cancer	1.74e-05	0.00045	CbGpPWpGaD
Nabumetone—PTGS2—Disease—JAG1—urinary bladder cancer	1.74e-05	0.000449	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	1.72e-05	0.000445	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ENO2—urinary bladder cancer	1.71e-05	0.000443	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—HPGDS—urinary bladder cancer	1.71e-05	0.000443	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.7e-05	0.00044	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.69e-05	0.000436	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	1.68e-05	0.000434	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTT1—urinary bladder cancer	1.66e-05	0.00043	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.64e-05	0.000423	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.47e-05	0.00038	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTP1—urinary bladder cancer	1.45e-05	0.000375	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.4e-05	0.000363	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.38e-05	0.000357	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—TYMS—urinary bladder cancer	1.35e-05	0.000349	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.35e-05	0.000348	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.34e-05	0.000347	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GSTM1—urinary bladder cancer	1.33e-05	0.000345	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NCOR1—urinary bladder cancer	1.33e-05	0.000345	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.29e-05	0.000333	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.28e-05	0.00033	CbGpPWpGaD
Nabumetone—PTGS2—Disease—NCOR1—urinary bladder cancer	1.26e-05	0.000327	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.25e-05	0.000324	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.21e-05	0.000313	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ERCC2—urinary bladder cancer	1.19e-05	0.000307	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.18e-05	0.000305	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.17e-05	0.000302	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.15e-05	0.000298	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MTHFR—urinary bladder cancer	1.12e-05	0.000289	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.11e-05	0.000288	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TERT—urinary bladder cancer	1.11e-05	0.000288	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.07e-05	0.000277	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.06e-05	0.000274	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.06e-05	0.000274	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.05e-05	0.000271	CbGpPWpGaD
Nabumetone—PTGS2—Disease—FGFR3—urinary bladder cancer	1.02e-05	0.000264	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.01e-05	0.000262	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ERCC2—urinary bladder cancer	9.96e-06	0.000257	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ENO2—urinary bladder cancer	9.7e-06	0.000251	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	9.7e-06	0.000251	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.64e-06	0.000249	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PPARG—urinary bladder cancer	9.56e-06	0.000247	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	9.41e-06	0.000243	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—MTHFR—urinary bladder cancer	9.36e-06	0.000242	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.26e-06	0.000239	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CREBBP—urinary bladder cancer	9.18e-06	0.000237	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CREBBP—urinary bladder cancer	8.71e-06	0.000225	CbGpPWpGaD
Nabumetone—PTGS2—Disease—RHOA—urinary bladder cancer	7.88e-06	0.000203	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NQO1—urinary bladder cancer	7.82e-06	0.000202	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PPARG—urinary bladder cancer	7.59e-06	0.000196	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.59e-06	0.000196	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTGS2—urinary bladder cancer	7.52e-06	0.000194	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CREBBP—urinary bladder cancer	7.29e-06	0.000188	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ERBB2—urinary bladder cancer	7.29e-06	0.000188	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.62e-06	0.000171	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTEN—urinary bladder cancer	6.56e-06	0.000169	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	6.52e-06	0.000168	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.31e-06	0.000163	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—EP300—urinary bladder cancer	6.25e-06	0.000162	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CDKN1A—urinary bladder cancer	6.23e-06	0.000161	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PTEN—urinary bladder cancer	6.22e-06	0.000161	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TYMS—urinary bladder cancer	6.06e-06	0.000157	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	5.99e-06	0.000155	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	5.99e-06	0.000155	CbGpPWpGaD
Nabumetone—PTGS2—Disease—EP300—urinary bladder cancer	5.93e-06	0.000153	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SRC—urinary bladder cancer	5.77e-06	0.000149	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GPX1—urinary bladder cancer	5.74e-06	0.000148	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	5.63e-06	0.000146	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	5.3e-06	0.000137	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PTEN—urinary bladder cancer	5.21e-06	0.000135	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MYC—urinary bladder cancer	5.17e-06	0.000133	CbGpPWpGaD
Nabumetone—PTGS2—Disease—EGFR—urinary bladder cancer	5.05e-06	0.000131	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—EP300—urinary bladder cancer	4.97e-06	0.000128	CbGpPWpGaD
Nabumetone—PTGS2—Disease—KRAS—urinary bladder cancer	4.77e-06	0.000123	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PPARG—urinary bladder cancer	4.29e-06	0.000111	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	4.13e-06	0.000107	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HRAS—urinary bladder cancer	4.06e-06	0.000105	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	3.38e-06	8.73e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTEN—urinary bladder cancer	2.95e-06	7.61e-05	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—EP300—urinary bladder cancer	2.81e-06	7.26e-05	CbGpPWpGaD
